Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/16/2017 11/17/2017 11/20/2017 11/21/2017 11/22/2017 Date
61.87(c) 61.32(c) 60.8(c) 61.24(c) 61.14(c) Last
4 286 221 4 147 934 4 902 710 3 967 968 3 054 505 Volume
+1.31% -0.89% -0.85% +0.72% -0.16% Change
More quotes
Financials ($)
Sales 2017 20 634 M
EBIT 2017 5 598 M
Net income 2017 4 351 M
Debt 2017 295 M
Yield 2017 2,58%
Sales 2018 21 272 M
EBIT 2018 5 838 M
Net income 2018 4 912 M
Finance 2018 1 373 M
Yield 2018 2,72%
P/E ratio 2017 23,48
P/E ratio 2018 20,49
EV / Sales2017 4,86x
EV / Sales2018 4,64x
Capitalization 100 B
More Financials
Company
Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.It includes chemically-synthesized drugs or small molecules and products produced from biological... 
Sector
Pharmaceuticals
Calendar
01/25Earnings Release
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
05:49a BRISTOL MYERS SQUIBB : New Chemistry Method Simplifies Late-Stage Modification o..
11/22 BRISTOL MYERS SQUIBB : to Take Part in Evercore ISI Biopharma Conference
11/21 First Data for NKTR-214 in Combination with OPDIVO® nivolumab for Patients wi..
11/21 BRISTOL MYERS SQUIBB : An Application for the Trademark "BRIPALO" Has Been Filed..
11/21 SYNGENE INTERNATIONAL : Bristol-Myers Squibb and Syngene International Expand On..
11/20 Innate Pharma SA - Third quarter 2017 report
11/17 LABORATORY OF AMERICA : LabCorp Announces New Expanded Use for PD-L1 Test with B..
11/16 BRISTOL MYERS SQUIBB : Opdivo Plus Yervoy Combination Delivered Overall Survival..
11/16 BRISTOL MYERS SQUIBB : Trademark Application for "ACCESS VIROLOGY" Filed
11/16 BRISTOL MYERS SQUIBB : Opdivo nivolumab Demonstrates Superior Three-Year Surviva..
More news
Sector news : Pharmaceuticals - NEC
10:27a German chemicals companies should review British ops - trade body
08:49aDJGLAXOSMITHKLINE : Files Additional Trelegy Ellipta Application to FDA
11/22 BAYER : Brazil pushes back decision on Bayer-Monsanto tie-up
11/22 European shares retreat on euro bounce; UK flat after budget
11/22 FTSE gets sterling boost, land purchase threat dents housebuilders
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB COMPA 
BRISTOL-MYERS SQUIBB CO - 2016
Attractive price levels
BUY
More Strategies
News from SeekingAlpha
11/22 Cabozantinib Franchise Will Continue To Transform Exelixis' Fortunes In 2018
11/22 Mystery Stocks Revealed In My 88 Stock Portfolio Along With 2018 Income Estim..
11/21 YOUR DAILY PHARMA SCOOP : Roche Rallies, Alnylam Granted BTD, Celsion Soars
11/20 Roche Rocks On With More Good News
11/20 Pfizer Scores Sutent Win, But Bristol-Myers Looks To Steal Its Thunder
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 63,1 $
Spread / Average Target 3,2%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY4.79%100 068
JOHNSON & JOHNSON20.08%368 832
NOVARTIS12.75%219 874
ROCHE HOLDING LTD.4.90%215 394
PFIZER9.42%211 188
MERCK AND COMPANY-7.64%148 286